Dynamic circulating tumor DNA indicates pathological benefits of additional neoadjuvant chemoimmunotherapy courses for locally advanced non-small-cell lung cancer patients
{{output}}
Introduction: Few studies have focused on the optimal cycles of neoadjuvant chemoimmunotherapy (NCI). This study introduced minimal residual disease (MRD) based on circulating tumor DNA (ctDNA), and investigated the association b... ...
